State of New Jersey Common Pension Fund D Takes Position in Kymera Therapeutics, Inc. $KYMR

State of New Jersey Common Pension Fund D bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the fourth quarter, Holdings Channel reports. The fund bought 33,538 shares of the company’s stock, valued at approximately $2,610,000.

A number of other hedge funds have also modified their holdings of the stock. Moody Aldrich Partners LLC grew its holdings in shares of Kymera Therapeutics by 33.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 38,535 shares of the company’s stock worth $2,998,000 after acquiring an additional 9,625 shares during the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of Kymera Therapeutics by 39.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 483,199 shares of the company’s stock worth $37,791,000 after acquiring an additional 136,382 shares during the last quarter. UBS Group AG grew its holdings in shares of Kymera Therapeutics by 13.6% in the 4th quarter. UBS Group AG now owns 737,032 shares of the company’s stock worth $57,348,000 after acquiring an additional 88,314 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Kymera Therapeutics by 8.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 24,524 shares of the company’s stock worth $1,908,000 after acquiring an additional 1,992 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Morgan Stanley restated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a report on Thursday, April 30th. Piper Sandler lifted their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. BTIG Research decreased their target price on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Stephens lifted their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Finally, UBS Group lifted their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.10.

Insiders Place Their Bets

In other news, insider Noah Goodman sold 1,347 shares of the firm’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $90.00, for a total value of $121,230.00. Following the completion of the sale, the insider owned 50,195 shares of the company’s stock, valued at $4,517,550. This trade represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Jeremy G. Chadwick sold 300 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $90.00, for a total value of $27,000.00. Following the completion of the sale, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at approximately $5,508,180. This trade represents a 0.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 380,734 shares of company stock worth $32,193,902. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Stock Up 4.3%

Shares of Kymera Therapeutics stock opened at $86.26 on Thursday. The stock has a market cap of $7.10 billion, a PE ratio of -24.16 and a beta of 2.06. The business has a fifty day simple moving average of $84.38 and a 200-day simple moving average of $76.79. Kymera Therapeutics, Inc. has a 12 month low of $28.06 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.Kymera Therapeutics’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.82) earnings per share. Analysts expect that Kymera Therapeutics, Inc. will post -3.34 EPS for the current fiscal year.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Canaccord Genuity initiated coverage with a “Buy” rating and a $106 price target (roughly mid‑teens upside vs. current levels), which can attract new buyers and raise investor visibility. Canaccord Coverage
• Positive Sentiment: HC Wainwright raised several near‑term EPS forecasts (Q2–Q4 2026 and FY2026) and lifted mid‑range year estimates (FY2027–FY2028), signaling improving analyst expectations for cash flow trajectory and program progress. This upgrade momentum supports sentiment. HC Wainwright Note
• Positive Sentiment: Kymera presented new preclinical IBD data for KT‑579 at Digestive Disease Week showing activity comparable or superior to approved/clinically active therapies — a potentially material data point for the IRF5 degrader program’s clinical prospects. KT-579 Preclinical Data
• Neutral Sentiment: Kymera will participate in multiple investor conferences this month (fireside chats) — increases management access to investors but is informational rather than catalytic by itself. Investor Conferences
• Negative Sentiment: Some analyst notes trimmed longer‑term estimates: HC Wainwright lowered FY2030 EPS (from $1.34 to $1.07) and made small adjustments to FY2029 — these cuts temper late‑cycle upside expectations and highlight forecasting uncertainty for commercialization/timing. Longer‑Term Estimate Changes

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.